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Abstract
Purpose—Evaluating genetic susceptibility may clarify effects of known environmental factors 
and also identify individuals at high risk. We evaluated the association of four insulin-related 
pathway gene polymorphisms in insulin-like growth factor-1 (IGF-I) (CA)n repeat, insulin-like 
growth factor-2 (IGF-II) (rs680), insulin-like growth factor binding protein-3 (IGFBP-3) 
(rs2854744), and adiponectin (APM1 rs1501299) with colon cancer risk, as well as relationships 
with circulating IGF-I, IGF-II, IGFBP-3, and C-peptide in a population-based study.
Methods—Participants were African Americans (231cases, 306 controls) and Whites (297 cases, 
530 controls). Consenting subjects provided blood specimens, and lifestyle/diet information. 
Genotyping for all genes except IGF-I was performed by the 5′-exonuclease (Taqman) assay. The 
IGF-I (CA)n repeat was assayed by PCR, and fragment analysis. Circulating proteins were 
measured by enzyme immunoassays. Odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated by logistic regression.
Results—The IGF-I (CA)19 repeat was higher in White controls (50%) than African American 
controls (31%). Whites homozygous for the IGF-I (CA)19 repeat had a nearly two fold increase in 
risk of colon cancer (OR=1.77; 95%CI=1.15–2.73), but not African Americans (OR= 0.73, 95%CI 
0.50–1.51). We observed an inverse association between the IGF-II Apa1 A-variant and colon 
cancer risk (OR= 0.49, 95%CI 0.28–0.88) in Whites only. Carrying the IGFBP-3 variant alleles 
Corresponding Author: Temitope O. Keku, Center for Gastrointestinal Biology & Disease, CB#7032, 7430-C Medical Biomolecular 




Cancer Causes Control. Author manuscript; available in PMC 2014 October 29.
Published in final edited form as:






















was associated with lower IGFBP-3 protein levels, a difference most pronounced in Whites (p- 
trend < 0.05).
Conclusions—These results support an association between insulin pathway-related genes and 
elevated colon cancer risk in Whites but not in African Americans.
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Introduction
For reasons that are as yet unclear, colorectal cancer incidence and mortality exhibit 
considerable race/ethnic variation, with the highest incidence in African Americans [1]. A 
combination of genetic, nutritional, and lifestyle factors may contribute to these differences 
[2]. However, most studies of colon cancer have been conducted in predominantly White 
populations that included few or no African Americans. Functional dysregulation of the 
insulin and the insulin-like growth factor (IGF) axis, which are major determinants of 
proliferation and apoptosis, have been hypothesized as a potential mechanism underlying 
colorectal carcinogenesis [2, 3]. We previously showed that elevated fasting insulin levels 
predicted increased risk of adenomas or colon cancer precursors [4]. Several epidemiologic 
studies including case-control [5, 6, 7] and cohort studies [8–13] have also evaluated the 
relationship between colon cancer, IGFs, and factors related to obesity and insulin resistance 
[14]. While the majority of these studies have reported modest positive associations [10–12, 
15], other reports have found no associations [9, 11]. These inconsistent findings may be 
due, in part, to the complex and non-complementary relationship between components of the 
IGF axis, and genetic and environmental factors inherent in different ethnic/racial groups.
Investigating genetic factors related to the insulin–IGF pathway, including insulin-like 
growth factor-1 (IGF-I), insulin-like growth factor-2 (IGF-II), insulin-like growth factor 
binding protein-3 (IGFBP-3), adiponectin (APM1)- and their influence on their protein 
products circulating levels, in diverse cohorts, may help clarify previously reported 
inconsistent associations and also identify individuals at high risk. Insulin, IGF-I and IGF-II 
are growth factors that regulate cell proliferation, apoptosis, transformation and 
differentiation [16]. Insulin-like growth factor binding proteins (IGFBPs), primarily 
IGFBP-3 modulates the function of the IGFs [17]. IGF-I has a microsatellite (CA)n repeat 
polymorphism in the promoter region [18] shown to influence IGF-I production [19–25]. 
Similarly, a single nucleotide polymorphism (SNP) in IGFBP-3, -202A>C, is linked with 
low plasma IGFBP-3 levels [26, 27]. IGF-II is over-expressed in colon cancer [28, 29]. 
While loss of imprinting of the IGF-II gene may account for this observation [30, 31], an 
Apa1 polymorphism located in exon 9 of the IGF-II gene may also contribute [32], but has 
not been evaluated in relation to colon cancer. An equally attractive candidate gene is 
adiponectin (APM1), which encodes for an adipose secreted cytokine, adiponectin. This 
cytokine plays a key role in the regulation of glucose, metabolism of fatty acids [33], insulin 
resistance and inflammation. An intron 2 polymorphism (+ 276 G>T) in the APM1 gene, is 
associated with high circulating adiponectin levels and improved insulin sensitivity [34–36]. 
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These insulin pathway-related genes and SNPs therein have been linked to colon cancer in 
smaller or Whites and Asian only studies [37–45].
Herein, we examined the association between polymorphisms in IGF-I (CA)n repeat, IGF-II 
(rs680), IGFBP-3 (rs2854744), and adiponectin (APM1 rs1501299) genes known to be 
either non-synonymous, or to influence protein production, and colon cancer risk. We 
hypothesized that genetic polymorphisms of these four SNPs may explain, at least in part, 
some of the racial/ethnic disparities in colon cancer incidence. In this study which included a 
large number of African Americans and Whites, we also examined the functional 
significance of these polymorphisms by examining their associations with circulating levels 
of IGF-I, IGF-II, IGFBP-3, and C-peptide among African American and white controls.
Methods
Study Population
Participants were enrollees of the North Carolina Colon Cancer Study – (NCCCS), a 
population based case-control study of participants from 33 contiguous counties of central 
North Carolina. Details of the study were previously published [35, 36]. Briefly, cases were 
ascertained through the North Carolina Central Cancer Registry rapid ascertainment system 
and consisted of persons with a first diagnosis of histologically confirmed invasive 
adenocarcinoma of the colon, between July 1996 and June 2000. All cases were between the 
ages of 40 and 85 at the time of diagnosis, residents of the 33-county study area, mentally 
competent to give informed consent and complete the interview, and possessed a North 
Carolina driver’s license or identification card. Controls younger than 65 years were 
randomly selected form the Division of Motor Vehicle records. The Health Care Financing 
Administration was the source for selecting controls aged 65 and older. They were 
frequency matched to cases by race, sex and 5-year age group. Completed interviews were 
obtained from 1,691 persons (634 cases and 1,048 controls), of whom 43% were African 
American. The overall study cooperation rate [interviewed/(interviewed + refused)] was 
84% for cases and 63% for controls, whereas the response rate (interviewed/eligible) was 
72% for cases and 61% for controls. Both cooperation and response rates were slightly 
higher for Whites than for African Americans, and reasons for the 12% difference in 
cooperation rate and response rate for cases included refusal to participate, MD (doctor) 
denied access to patient, untraceable or unable to contact as previously described [46, 47].
Data Collection
In-home-interviews were conducted by trained nurses to collect information about lifestyle 
and diet, as well as collect blood specimens under non-fasting conditions. A health history 
questionnaire was used to collect information on physical activity, anthropometric 
measurements (weight, height, waist, and hip), medical information, demographic 
information, smoking habits, family history, diabetes history, physical activity, NSAIDs use, 
and other factors that might relate to both colon cancer incidence and mortality. Detailed 
dietary information was collected using a modified version of the semi-quantitative food 
frequency questionnaire developed at the National Cancer Institute [48, 49]. The diet 
questionnaire was used to assess the frequencies and amounts of over 100 food items 
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consumed during the year prior to diagnosis for cases with colon cancer or during the 
previous year for control subjects. A one-year period was chosen to provide a full cycle of 
seasons so that responses would be independent of the time of the year [50]. Nutrient intake 
was analyzed by the National Cancer Institute program, which incorporated the nutrient 
content of each food item, the consumption frequency, and a portion size based on age.
Blood Specimens
Blood samples were collected from consenting participants at the time of the interview. 
Cases were enrolled within 6 months of diagnosis. Blood was kept in coolers with cold 
packs until delivered to the laboratory for processing. Subjects who preferred to have the 
blood draw in their doctor’s office were provided a FedEx® specimen package for blood 
draw, and the blood specimens were shipped to the lab on cold packs. Blood was usually 
received and processed in the lab within 24 hours. Plasma samples were stored in aliquots at 
−80°C. The compliance rates for blood collection were 86% for cases and 83% for controls. 
Participants who gave blood were more likely to be male, White, and to have never smoked 
compared with those who did not give blood. These groups did not differ according to 
dietary intake or other risk factors including stage at diagnosis in cases. Odds ratios for 
colon cancer and dietary and other risk factors did not differ between those who gave blood 
and those who did not (data not shown).
DNA extraction
Genomic DNA was extracted from peripheral blood leukocytes using the PureGene DNA 
isolation kit (Gentra Systems, Inc., Minneapolis, MN).
Genotyping
Genotyping was performed using the ABI 7700 Sequence Detection System 5′ exonuclease 
(Taqman™) assay. IGF-II, IGFBP-3 and APM1 (Adiponectin) primers and probes were 
designed using Primer Express™ oligonucleotide design software (Applied Biosystems, 
Forster City, CA). For IGF-II the probe was 5′-AAAAGAAGGGCCCCAGA -3′, the F-
primer was 5′-GAGTCCCTGAACCAGCAAAGAG -3′, and the R-primer was 5′-
AAATTCCCGTGAGAAGGGAGAT-3′. For IGFBP-3, the probe, the F- and R- primers 
were: 5′-CTCGTGCTCACGCC -3′; 5′-ACACCTTGGTTCTTGTAGACGACAA -3′, and 
5′-GGCGTGCAGCTCGAGACT -3′, respectively. The assay design and conditions were 
based on the allelic discrimination protocol from Applied Biosystems. Similar PCR reaction 
conditions were used for these genotype assays. Briefly, reactions were performed in a final 
volume of 15μl containing 30 ng of genomic DNA, 900nM of each primer, 100nM of each 
probe, and 0.7X Taqman Universal PCR Master Mix. Amplifications were performed on 
Perkin Elmer GenAmp® 9700 thermocyclers using the 9600 mode under the following 
conditions: 50°C for 2 minutes (AmpErase® UNG), 95°C for 10 minutes followed by 35 
cycles of 95°C for 15 seconds, and 64°C for 1 minute.
For Adiponectin genotyping, PCR primers and probes were commercially designed by 
Assays by Design (Applied Biosystems), and as such the probe and primer sequences are 
proprietary. The reaction components were as follows: 2X Taqman Universal PCR master 
mix, 20X Applied Biosystems primer and probe mix and 15 ng of genomic DNA. The 
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reaction conditions were as follows: 50°C for 2 minutes, 1 cycle of 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute.
For all Taqman genotyping assays, plates were read on the ABI 7700 using the allele 
discrimination protocol. Six of each non-template (water) controls and amplification/
genotype controls were included in each run. Positive controls included DNA samples from 
the Coriell tissue repository that have been previously sequenced by SNP500 cancer [51]. 
All samples were successfully amplified and genotyped. For each gene, assays were also 
repeated on 10% of randomly selected samples, and the results were 100% concordant.
IGF-I (CA)19 genotyping methods
Analysis of the cytosine-adenine (CA)n repeats of the IGF-I gene, located 1 kb upstream 
from the transcription start site was performed using PCR and fragment analysis. The PCR 
reactions performed in 50μl volumes, consisted of 10 ng of genomic DNA using 125 nM of 
each primer (fluorescently labeled forward primer, 5′ 6-FAM-
GCTAGCCAGCTGGTGTTATT-3 and reverse, 5′-ACCACTCTGGGAGAAGGGTA-3), 
100 μM dNTPs, 1.5 mM MgCl2, and 1.5 units of AmpliTaq Gold polymerase (ABI Applied 
Biosystems), and standard PCR buffer. Amplification cycles included one cycle of 15 
minutes at 95°C, 35 cycles consisting of 30 seconds at 95°C (denaturation), 30 seconds at 
64°C (annealing), and 1 minute at 72°C (elongation), and a final elongation step at 72°C for 
7 minutes. Amplified PCR products were purified over QIAquick purification columns 
(Qiagen), followed by a 1:100 dilution. The diluted product (10μl) was mixed with loading 
buffer (80% formamide, 5mM EDTA, 50 ug/uL Blue Dextran) and ROX GeneScan-350 size 
standard (ABI) followed by denaturing for 5 minutes at 95°C and capillary electrophoresis 
on the ABI-3600 genetic analyzer. Fragment sizing was determined by Genescan analyses 
software (ABI Applied Biosystems). The fragments ranged in size from 174 to 202 base 
pairs, depending on the number of CA repeats.
DNA from representative homozygote individuals for the (CA)18, (CA)19, and (CA)20 
genotypes were sequenced to confirm the number of CA repeats. Quality control procedures 
were as follows, blinding of lab personnel to subjects’ case-control status, inclusion of 
positive and negative controls in each assay run, and review of genotype results by a second 
reviewer (TOK). In addition, 10% of samples were repeated blindly to validate the 
genotyping procedures. The concordance for the blinded repeat samples was 100%.
Enzyme Linked Immunosorbent Assays
Plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide were measured by ELISA using 
commercially available kits (DSL Inc. Webster, Texas). IGF-I and IGF-II were measured 
after acid-ethanol extraction to remove IGFBPs. These analytes were measured in duplicate 
on stored plasma samples and laboratory personnel were blinded to the case or control status 
of samples. Intra-assay coefficients of variation were 6.5% for IGF-I, 1.5% for IGF-II, 4.7% 
for IGFBP-3, and 5.7% for C-peptide. The inter-assay coefficient of variation was less than 
12% for all of the analytes measured. Previous epidemiologic studies have reported good 
reproducibility with these commercial kits [10, 52].
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For cases and controls, descriptive statistics were generated for age (<65 years/>=65 years), 
race (White/black), gender (male/female), family history (yes/no for at least one first-degree 
relative with colon cancer), diabetes history (yes/no), BMI one year ago or one year prior to 
diagnosis for cases (categorized into normal, overweight and obese), NSAID usage (use >= 
15 NSAIDs/month in past 5 years), alcohol use, (yes/no), and smoking status (never, former, 
current). Also, mean values as well as number above and below the median value (as 
determined by controls) was found for waist-hip ratio, physical activity as measured in 
MET-minutes per day, total daily calories, percentage of calories from fat, and total daily 
calcium intake. P-values were generated to compare cases and controls.
Allele frequencies were calculated as the number of copies of a particular allele divided by 
the total number of chromosomes (2N=two times the number of persons in the study). 
Genotype frequencies were calculated as the number of participants having each genotype 
divided by the total number of participants. Exact 95% confidence intervals for allele and 
genotype frequencies were computed by the method outlined by Collett [53]. Distributions 
for cases and controls were compared via chi-square tests. Observed genotype frequencies 
were compared to expected genotype frequencies, calculated on the basis of observed allelic 
frequencies, assuming Hardy-Weinberg equilibrium. Departure from Hardy-Weinberg 
equilibrium was tested among control groups using a goodness-of-fit chi-square test.
Unconditional logistic regression models were used to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) for the association between carrying the variant allele and risk of 
colon cancer. We compared carriers of at least one of the minor alleles (at risk genotype) to 
individuals homozygous for the common allele (referent genotype). All statistical models 
were adjusted for colon cancer risk confounders in the population, including age at reference 
date, sex and race; race was excluded from race-stratified models. Factors previously 
reported to be associated with colon cancer including body mass index (BMI = kg/m2) and 
NSAID use were explored for effect modification using stratified analyses. These factors 
were then evaluated for confounding (together with family history, alcohol use, fat calories, 
physical activity, caloric intake, diabetes history, age, race, and current and former cigarette 
smoking) comparing logistic regression models with and without the variables of interest. 
Regression models were used to evaluate the correlation between genotype and circulating 
protein concentrations, adjusting for potential confounders. SAS version 9.1 (SAS, Cary, 
NC, USA) was used for all statistical analyses.
Results
Descriptive characteristics of cases and controls are summarized in Table 1. Briefly, 48% of 
cases were less than 65 years of age compared to 38% of controls (p=0.0001); 43% of the 
553 cases compared to 38% of 875 controls were African American (p=0.001); and women 
comprised 48% of cases and 48% of controls. Cases did not differ considerably from 
controls with respect to diabetes, BMI recalled a year prior to the interview, waist/hip ratio, 
physical activity, and alcohol use. However, cases were more likely than controls to report a 
family history of colon cancer (21% vs 9%, respectively), higher average calorie 
consumption per day, and greater proportion of calories derived from fat. Sixty two percent 
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of cases were current or former cigarette smokers compared to 59% of controls (p=0.03), 
and cases were less likely to have used >=15 NSAIDS/month in the past five years (p=0.05).
The distribution of IGF-I (CA)19 polymorphism for African American and White cases and 
controls is shown in Figure 1. IGF-I (CA)n polymorphic repeats ranged from n=11 
(fragment size 174 bp) to n=24 repeats (fragment size 202 bp) and the most common repeat 
was n =19 (fragment size 192 bp) which was designated the referent allele. Overall, the IGF-
I (CA)19 allele was the most common, present in 46% of cases and 43% of controls. Among 
African Americans, 30% of cases and 31% of controls carried the IGF-I (CA)19 allele while 
the next most frequent allele, (CA)18, was found in 25% of cases and 26% of controls. 
Among Whites, 58% of cases and 50% of controls carried the (CA)19 allele while the next 
most frequent allele, (CA)20, had a distribution of 21% in cases and 25% in controls. 
Although, the IGF-I (CA)19 allele distribution differed by race with higher frequencies 
observed in Whites than African Americans, the distributions were similar to those 
published in the literature for Whites [25] and African Americans [54–57].
Sex, age, calories, NSAIDS and cigarette smoking adjusted ORs and 95%CI for associations 
between IGF-I, IGFBP-3, IGF-II and AMP1 genetic variants and colon cancer risk in 
African American and Whites, are shown in Table 2. Whites homozygous for the IGF-I 
(CA)19 repeat polymorphism had a nearly 2-fold, dose-dependent increased risk of colon 
cancer (OR=1.77; 95%CI=1.15–2.73). We also found a dose-dependent inverse association 
between homozygous carriers of the IGF-II Apa1 A-variant and colon cancer risk in Whites 
(OR= 0.49, 95%CI 0.28–0.88). These associations were not apparent in African Americans. 
We also found little evidence for associations between carrying the IGFBP-3 or the APM1 
variants and colon cancer risk in Whites and African Americans. None of the genotype 
distributions among controls deviated from Hardy Weinberg Equilibrium (IGF-II Apa1 
p=0.99, IGFBP-3 p=0.99, and AMP1 p=0.72).
Table 3 shows plasma levels of IGF-II, IGF-I, IGFBP-3, and C-peptide among controls 
carriers of IGF axis genes polymorphisms. Overall, circulating levels of IGF-I, IGF-II, 
IGFBP-3 and C-peptide were similar in Whites and African Americans. Within each ethnic/
race group, plasma concentrations of IGF-I and IGF-II also did not vary significantly by 
genotype. We then analyzed C-peptide concentrations, a stable surrogate for measuring 
insulin levels, in carriers of the AMP1 SNP, since polymorphisms of the adiponectin gene 
are associated with insulin resistance and type II diabetes [58, 59], known confounders of 
colon cancer risk. Compared to non-carriers, we observed lower C-peptide concentrations 
among carriers of the AMP1 genotype in African Americans (p=0.13) and Whites (p=0.36) 
although not statistically significant. In Whites, non-carriers of the IGFBP-3 variant had 
significantly higher plasma levels of IGFBP-3 (3543 ng/ml, SE=110) than either 
homozygous carriers (3188 ng/ml, SD=104, p=0.03) or heterozygous and homozygous 
carries (3239 ng/ml, SE=80) (p=0.008), an association not found in African American. The 
ratio of IGF-I/IGFBP-3 levels showed higher concentrations in White and not in African 
American carriers of the IGFBP-3 variant, however not in carriers of the IGF-I (CA)19 
repeat.
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In this population-based case control study, we evaluated the associations of four SNPs in 
IGF-I, IGF-II, IGFBP-3 and adiponectin, and colon cancer risk in African Americans and 
Whites. We also examined associations between these genotypes and their protein products 
among population controls. After adjusting for known confounders, we found that carrying 
the IGF1 (CA)19 repeat polymorphism was associated with an increase in colon cancer risk 
while carrying the IGF-II Apa1A variant was associated with lower risk. This association 
was limited to Whites. However, we found no evidence for an association between carrying 
these variants and circulating protein products, IGF1 and IGF2. We also found that carrying 
the IGFBP-3 and AMP1 variants was not associated with risk of colon cancer in either 
ethnic group. However, among otherwise healthy individuals, carrying the IGFBP-3 
polymorphism was associated with lower IGFBP-3 levels in Whites, and a trend for lower 
IGFBP-3 levels in African Americans. IGF-I/IGFBP-3 ratio concentrations were 
significantly higher in White carriers of the IGFBP-3 SNP, but no differences were observed 
in White carriers of the IGF1 (CA)19 repeat variant nor in African American carriers of 
these SNPs, indicating that the IGFBP-3 SNP may influence lower expression of IGFBP-3 
and perhaps colon cancer risk in Whites.
Although twin studies suggest that serum levels of IGF-I, IGF-II and IGFBP-3 may be 
influenced by a combination of genetic and environmental factors [21, 60–62], few 
epidemiologic studies have considered the impact of the genetic component on plasma 
levels when examining associations with colon cancer. To our knowledge, this is the first 
population-based study that includes a significantly large number of African Americans, to 
report on four insulin-pathway related genes polymorphisms and colon cancer risk and 
simultaneous evaluation of their influence on circulating protein plasma levels among 
controls. The frequencies for IGF-I (CA)19 repeat polymorphism in African Americans and 
Whites were within the ranges previously reported by others [25, 54, 55, 57] and HapMap 
[63]. Our findings that homozygosity for the IGF-I (CA)19 repeat polymorphism was 
associated with increased risk of colon cancer among Whites are consistent with the 
majority of studies that have evaluated the IGF-I(CA)19 repeat polymorphism and colon 
cancer [64] although the association with protein concentrations differ. While some studies 
reported correlation with reduced IGF-I levels [23, 25], others found that the IGF-I (CA)19 
repeat did not predict plasma levels [27, 65]. However, these findings are consistent with 
those of our previous reports where the effects of the IGF-I (CA)19 polymorphism on 
circulating concentrations of IGF-I varied considerably by race/ethnicity [66], and 
associated with prostate cancer risk [67]. A recent study in a Chinese population, further 
analyzed the potential causes of these ethnic differences and found that the IGF-I (CA)19 
repeat by itself is not the primary regulatory element of IGF-I expression [68]. The null 
results among African Americans in the present study, could be due to their lower frequency 
of the IGF-I (CA)19, repeat, or to recently identified factors, including other genetic variants 
in the IGF-I regulatory region which may be contributing to the regulation of IGF-I 
expression. In addition, the high degree of linkage disequilibrium in the IGF-I promoter 
region cannot be fully measured by association studies [68]. Furthermore, IGF-I/IGFBP-3 
ratio levels did not vary in African American and White carriers of the IGF-I (CA)19, repeat 
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SNP, however, IGF-I/IGFBP-3 ratio levels were higher in White carriers of the IGFBP-3 
SNP, suggesting that lower levels of IGFBP-3 may be influencing higher free IGF-I in 
circulation, a combination of factors that has been previously shown to be independently 
associated with an increased risk of colorectal adenoma and cancer in women [15].
Neither African American nor White carriers of the IGFBP-3 polymorphism had increased 
colon cancer risk. However, among otherwise healthy individuals, carriers in both 
populations had significantly lower IGFBP-3 plasma levels, compared to non-carriers, 
although a dose-dependent trend was not apparent. Lower circulating IGFBP-3 levels have 
been associated with poor prognosis among colorectal cancer patients receiving 
chemotherapy [69, 70] while higher IGFBP-3 plasma levels associated with decreased colon 
cancer risk [8, 13]. A human colorectal carcinogenesis genome-wide study recently 
identified missense mutations in the IGFBP-3 gene, which could be modulating IGFBP-3 
transcripts and subsequent protein expression [69]. These mutations could be in linkage 
disequilibrium with the IGFBP-3 polymorphism and thus explain the association between 
lower IGFBP-3 protein levels and CC risk in controls, however the IGFBP-3 polymorphism 
by itself was not associated with CC risk.
The role of the exon 9 Apa I polymorphism of the IGF-II gene in colon cancer is unclear, 
although some studies suggest that circulating levels of IGF-II and local tissue expression 
may be influenced by loss of imprinting [71]. In this study, the IGF-II Apa1 AA variant 
genotype was inversely associated with colon cancer risk among men and women 
particularly among Whites (data not shown). Those carrying the IGF-II Apa1 A-variant had 
somewhat lower circulating levels of this potent growth factor compared to those without 
the variant. This contrasts with the findings by Ma et. al. [10] who reported no association 
between IGF-II levels and colorectal cancer risk in a case-control study. It is possible that 
the influence of the A-variant on protein levels is less than what would be achieved by IGF-
II relaxation of imprint controls, since IGF-II is an imprinted gene.
Obesity, central adiposity, and increased energy intake are associated with elevated risk of 
colon cancer [3, 72, 73] via their effects on insulin levels, insulin resistance [74] and 
inflammation. Adiponectin, an adipose secreted cytokine, is responsible for enhanced insulin 
sensitization [75] and has been associated with known colon cancer risk factors namely 
obesity, type 2 diabetes, and inflammation [5, 76–80]. Plasma adiponectin levels have been 
evaluated relative to colon cancer with contradictory results. Wei et al. [81] observed that 
low plasma adiponectin was associated with increased risk of colorectal cancer among men, 
while another study observed no association between plasma adiponectin and colorectal 
cancer [82]. We reasoned that genetic variation in adiponectin may contribute to these 
conflicting reports. Several adiponectin variants have been shown to affect adiponectin 
levels and have been associated with insulin resistance, obesity, and type 2 diabetes [83]. 
However, few studies have evaluated adiponectin polymorphisms in relation to colon 
cancer. We examined a polymorphism in the adiponectin gene (276G>T) and observed a 
lower colon cancer risk in African American carriers of this variant. We also found a 
decrease in C-peptide for the T-allele in both African Americans and Whites. The T allele is 
associated with elevated levels of adiponectin [83, 84] and improved insulin sensitivity [78], 
therefore our findings of reduced plasma C-peptide among controls with the T-allele 
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supports previous observations. Recent reports showed that lower levels of prediagnosis 
plasma C-peptide among patients with surgically resected colorectal cancer associated with 
decreased mortality [85], whereas elevated concentrations of C-peptide may predict the risk 
of developing colorectal cancer [86], however genetic factors were not analyzed in these 
studies. Although our findings should be interpreted with caution since we measured non-
fasting C-peptide concentrations, mean levels (0.84 (0.72–0.96) pmol/mL and 0.92 (0.82–
1.01) pmol/mL) in African American and White controls, respectively) were strikingly 
similar to mean and fifth quintile levels reported by others [48] under the same non-fasting 
conditions (mean=0.70 (0.59–0.82) pmol/mL) (Q5=0.97 (0.74–2.02) pmol/mL). Our 
findings, even though not statistically significant showed that African American and White 
APMI variant carriers had lower levels of circulating C-peptide (0.73 (0.62–0.83) and 0.86 
(0.75–0.96) pmol/mL, respectively). Hara et al. [84] found that among subjects with high 
BMI, the GG genotype was related to increased insulin resistance and low levels of 
adiponectin.
Although this is not a genome-wide study, and we cannot exclude the influence of other 
genes or other SNPs in these pathways, only one measure of proteins was made, yet there 
may be considerable variation in plasma levels over time, and C-peptide levels were 
measured under non-fasting conditions. However, our results relating protein differences to 
colon cancer risk are compatible with observations from cohort [9, 10, 86, 87] and other 
case-control studies [88]. Our findings of racial differences in both the association of 
genotypes on colon cancer risk and effects on circulating protein levels are novel and 
contribute to the existing literature on insulin-IGF axis and insulin resistance-related factors 
strong associations with colon cancer. In a previous study of 70 African Americans and 
Caucasians, we found that the effect of genetic and lifestyle factors such as cigarette 
smoking and IGF-I CA repeats influenced IGF1 and IGFBP-3 plasma levels in one race 
group only [65].
In summary, this study provides evidence for associations between heritable insulin–IGF 
axis factors and colon cancer risk -a risk most pronounced in Whites. The association 
between the insulin-IGF axis genetic variants and circulating protein products will require 
replication in larger studies where ancestral markers are used to define race/ethnicity.
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Fig. 1. Distribution of IGF-I alleles among African Americans and Whites
IGF-I (CA)n polymorphic repeats ranged from n=11 (fragment size 174 bp) to n=24 repeats 
(fragment size 202 bp) and the most common repeat was n=19 (fragment size 192 bp). IGF-I 
(CA)19 is the most frequent allele among African American and Whites cases and controls
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